Glenmark Pharmaceuticals today said it has received final nod from US health regulator for its Clobetasol Propionate spray used for treatment of moderate to severe plaque psoriasis in adults.
Glenmark Pharmaceuticals Inc, USA has received final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate spray 0.05 per cent, the company said in a statement.
The product is generic version of Galderma Laboratories L P's Clobex spray in the same strength, it added.
This product will be manufactured at the Glenmark's Baddi plant in Himachal Pradesh.
"As per IQVIA sales data for the 12 month period ending January 2018, the Clobex spray, 0.05 per cent market that includes brand and all available therapeutic equivalents achieved annual sales of approximately USD 30.5 million," it said.
The company's portfolio consists of 131 products authorised for distribution in the US market and 63 ANDA's pending approval with the USFDA, Glenmark said.
The company's stock was trading 0.12 per cent up at Rs 539.95 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app